Literature DB >> 26294774

Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.

Julio Rosenstock1, Ele Ferrannini2.   

Abstract

Entities:  

Year:  2015        PMID： 26294774     DOI： 10.2337/dc15-1380

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  148 in total

Review 1.  Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review.

Authors:  Salvatore Carbone; Dave L Dixon; Leo F Buckley; Antonio Abbate
Journal:  Mayo Clin Proc       Date:  2018-11       Impact factor: 7.616

Review 2.  Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar.

Authors:  Tanya Wilcox; Christophe De Block; Arthur Z Schwartzbard; Jonathan D Newman
Journal:  J Am Coll Cardiol       Date:  2020-04-28       Impact factor: 24.094

Review 3.  Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering.

Authors:  Brendon L Neuen; David Z Cherney; Meg J Jardine; Vlado Perkovic
Journal:  CMAJ       Date:  2019-10-15       Impact factor: 8.262

Review 4.  SGLT2 inhibition and heart failure-current concepts.

Authors:  Joaquim Silva Custodio; Andre Rodrigues Duraes; Marconi Abreu; Natalia Albuquerque Rocha; Leonardo Roever
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 5.  Type 1 diabetes: where are we in 2017?

Authors:  Melanie Copenhaver; Robert P Hoffman
Journal:  Transl Pediatr       Date:  2017-10

6.  Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.

Authors:  Jenny E Blau; Sri Harsha Tella; Simeon I Taylor; Kristina I Rother
Journal:  Diabetes Metab Res Rev       Date:  2017-09-29       Impact factor: 4.876

Review 7.  Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management.

Authors:  Katie M Murphy; Julie L Rosenthal
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-07

Review 8. 

Authors:  Noah M Ivers; Maggie Jiang; Javed Alloo; Alexander Singer; Daniel Ngui; Carolyn Gall Casey; Catherine H Yu
Journal:  Can Fam Physician       Date:  2019-01       Impact factor: 3.275

Review 9.  Diabetes Canada 2018 clinical practice guidelines: Key messages for family physicians caring for patients living with type 2 diabetes.

Authors:  Noah M Ivers; Maggie Jiang; Javed Alloo; Alexander Singer; Daniel Ngui; Carolyn Gall Casey; Catherine H Yu
Journal:  Can Fam Physician       Date:  2019-01       Impact factor: 3.275

10.  [Severe atypical ketoacidosis due to SGLT2-inhibitor therapy : Two case reports].

Authors:  T G K Breuer; K Kampmann; A Wutzler; C Steinfort; W Uhl; W E Schmidt; J J Meier
Journal:  Internist (Berl)       Date:  2018-03       Impact factor: 0.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.